Back to search
FDAFDA · Food and drugs·Recall number Z-1594-2024

Microalbumin Calibrator Series (mALB CAL)-IVD to calibrate the Microalbumin Assay Catalog Number: MA2426

Published April 24, 2024 · Recall initiated: January 31, 2024

Summary

FDA records medical device Class II recall Z-1594-2024, published April 24, 2024 and initiated January 31, 2024. Recalling firm: Randox Laboratories Ltd.; Status: Ongoing; Reported quantity: 6 units; Lot: GTIN: 05055273204544 (1) Batch/Lot: 602114 /1083MA-1087MA (2) Batch/Lot: 636645 /1108MA-1112MA (3) Batch/Lot: 662429 /1083MA- 1087MA. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Ongoing — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Microalbumin Calibrator Series, MA1567 & MA2426, is running with a negative bias compared to other method may misclassify patient results. Users may experience a shift in Quality Control and patient sample recovery of up to +12%.

What to do

Voluntary: Firm initiated · E-Mail

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Randox Laboratories Ltd.
Distributor
US Nationwide distribution in the states of GA, MA, WV including PR.
Lot
GTIN: 05055273204544 (1) Batch/Lot: 602114 /1083MA-1087MA (2) Batch/Lot: 636645 /1108MA-1112MA (3) Batch/Lot: 662429 /1083MA- 1087MA
Risk classification
Class II
Area (FDA)
device
Country
Ireland

Related recalls

Questions about this recall

Was Microalbumin Calibrator Series (mALB CAL)-IVD to calibrate the Microalbumin Assay Catalog Number: MA2426 recalled?

Yes. FDA published recall Z-1594-2024 on April 24, 2024. Reported hazard: Microalbumin Calibrator Series, MA1567 & MA2426, is running with a negative bias compared to other method may misclassify patient results. Users may experience a shift in Quality Control and patient sample recovery of up to +12%.

What should I do if I have this product?

Voluntary: Firm initiated · E-Mail